APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pneumococcal Vaccine Polyvalent

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Pneumococcal Vaccine Polyvalent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025171 pages

Choose your research edition.

Industry ResearchPneumococcal Vaccine Polyvalent Industry Research Report 2026109 pages · $2,950 USDIndustry Growth & TrendsGlobal Pneumococcal Vaccine Polyvalent Industry Growth and Trends Forecast to 203272 pages · $3,450 USDMarket StructureGlobal Pneumococcal Vaccine Polyvalent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032171 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pneumococcal Vaccine Polyvalent Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Pneumococcal Vaccine Polyvalent Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Pneumococcal Vaccine Polyvalent market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Pneumococcal Vaccine Polyvalent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pneumococcal Vaccine Polyvalent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pneumococcal Vaccine Polyvalent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Pneumococcal Vaccine Polyvalent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Pneumococcal Vaccine Polyvalent include Merck & Co. and Pfizer among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pneumococcal Vaccine Polyvalent market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pneumococcal Vaccine Polyvalent and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pneumococcal Vaccine Polyvalent sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pneumococcal Vaccine Polyvalent market size, projected growth trends, production technologies, key applications, and end-use industries.

Pneumococcal Vaccine Polyvalent Segment by Company

Merck & Co.

Pfizer

Pneumococcal Vaccine Polyvalent Segment by Type

Prevnar 13

Pneumovax23

Pneumococcal Vaccine Polyvalent Segment by Application

65 Years and Older

19 To 64 Years Old

18 Years and Younger

Pneumococcal Vaccine Polyvalent Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumococcal Vaccine Polyvalent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pneumococcal Vaccine Polyvalent and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumococcal Vaccine Polyvalent.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pneumococcal Vaccine Polyvalent market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Pneumococcal Vaccine Polyvalent manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Pneumococcal Vaccine Polyvalent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Pneumococcal Vaccine Polyvalent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Pneumococcal Vaccine Polyvalent Industry Trends Table 2. Pneumococcal Vaccine Polyvalent Industry Drivers Table 3. Pneumococcal Vaccine Polyvalent Industry Opportunities and Challenges Table 4. Pneumococcal Vaccine Polyvalent Industry Restraints Table 5. Global Pneumococcal Vaccine Polyvalent Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Pneumococcal Vaccine Polyvalent Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Manufacturers Table 9. Global Pneumococcal Vaccine Polyvalent Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Pneumococcal Vaccine Polyvalent Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Pneumococcal Vaccine Polyvalent Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Pneumococcal Vaccine Polyvalent Manufacturers, Product Type & Application Table 13. Global Pneumococcal Vaccine Polyvalent Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Pneumococcal Vaccine Polyvalent by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Prevnar 13 Table 17. Major Manufacturers of Pneumovax23 Table 18. Global Pneumococcal Vaccine Polyvalent Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 19. Global Pneumococcal Vaccine Polyvalent Sales by Type (2021-2026) & (W Units) Table 20. Global Pneumococcal Vaccine Polyvalent Sales by Type (2027-2032) & (W Units) Table 21. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Type (2021-2026) Table 22. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Type (2027-2032) Table 23. Global Pneumococcal Vaccine Polyvalent Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 24. Global Pneumococcal Vaccine Polyvalent Revenue by Type (2021-2026) & (W Units) Table 25. Global Pneumococcal Vaccine Polyvalent Revenue by Type (2027-2032) & (W Units) Table 26. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Type (2021-2026) Table 27. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of 65 Years and Older Table 29. Major Manufacturers of 19 To 64 Years Old Table 30. Major Manufacturers of 18 Years and Younger Table 31. Global Pneumococcal Vaccine Polyvalent Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 32. Global Pneumococcal Vaccine Polyvalent Sales by Application (2021-2026) & (W Units) Table 33. Global Pneumococcal Vaccine Polyvalent Sales by Application (2027-2032) & (W Units) Table 34. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Application (2021-2026) Table 35. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Application (2027-2032) Table 36. Global Pneumococcal Vaccine Polyvalent Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 37. Global Pneumococcal Vaccine Polyvalent Revenue by Application (2021-2026) & (W Units) Table 38. Global Pneumococcal Vaccine Polyvalent Revenue by Application (2027-2032) & (W Units) Table 39. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Application (2021-2026) Table 40. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Application (2027-2032) Table 41. Global Pneumococcal Vaccine Polyvalent Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 42. Global Pneumococcal Vaccine Polyvalent Sales by Region (2021-2026) & (W Units) Table 43. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Region (2021-2026) Table 44. Global Pneumococcal Vaccine Polyvalent Sales Forecasted by Region (2027-2032) & (W Units) Table 45. Global Pneumococcal Vaccine Polyvalent Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Pneumococcal Vaccine Polyvalent Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 47. North America Pneumococcal Vaccine Polyvalent Sales by Country (2021-2026) & (W Units) Table 48. North America Pneumococcal Vaccine Polyvalent Sales by Country (2027-2032) & (W Units) Table 49. Europe Pneumococcal Vaccine Polyvalent Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 50. Europe Pneumococcal Vaccine Polyvalent Sales by Country (2021-2026) & (W Units) Table 51. Europe Pneumococcal Vaccine Polyvalent Sales by Country (2027-2032) & (W Units) Table 52. Asia Pacific Pneumococcal Vaccine Polyvalent Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 53. Asia Pacific Pneumococcal Vaccine Polyvalent Sales by Country (2021-2026) & (W Units) Table 54. Asia Pacific Pneumococcal Vaccine Polyvalent Sales by Country (2027-2032) & (W Units) Table 55. South America, Middle East and Africa Pneumococcal Vaccine Polyvalent Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 56. South America, Middle East and Africa Pneumococcal Vaccine Polyvalent Sales by Country (2021-2026) & (W Units) Table 57. South America, Middle East and Africa Pneumococcal Vaccine Polyvalent Sales by Country (2027-2032) & (W Units) Table 58. Global Pneumococcal Vaccine Polyvalent Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Pneumococcal Vaccine Polyvalent Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Pneumococcal Vaccine Polyvalent Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Region (2021-2026) Table 62. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Region (2027-2032) Table 63. Merck & Co. Company Information Table 64. Merck & Co. Business Overview Table 65. Merck & Co. Pneumococcal Vaccine Polyvalent Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Merck & Co. Pneumococcal Vaccine Polyvalent Product Portfolio Table 67. Merck & Co. Recent Development Table 68. Pfizer Company Information Table 69. Pfizer Business Overview Table 70. Pfizer Pneumococcal Vaccine Polyvalent Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Pfizer Pneumococcal Vaccine Polyvalent Product Portfolio Table 72. Pfizer Recent Development Table 73. Key Raw Materials Table 74. Raw Materials Key Suppliers Table 75. Pneumococcal Vaccine Polyvalent Distributors List Table 76. Pneumococcal Vaccine Polyvalent Customers List Table 77. Research Programs/Design for This Report Table 78. Authors List of This Report Table 79. Secondary Sources Table 80. Primary Sources List of Figures Figure 1. Pneumococcal Vaccine Polyvalent Product Image Figure 2. Global Pneumococcal Vaccine Polyvalent Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pneumococcal Vaccine Polyvalent Market Size (2021-2032) & (US$ Million) Figure 4. Global Pneumococcal Vaccine Polyvalent Sales (2021-2032) & (W Units) Figure 5. Global Pneumococcal Vaccine Polyvalent Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Pneumococcal Vaccine Polyvalent Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Prevnar 13 Image Figure 9. Pneumovax23 Image Figure 10. Global Pneumococcal Vaccine Polyvalent Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 11. Global Pneumococcal Vaccine Polyvalent Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Type (2021-2032) Figure 13. Global Pneumococcal Vaccine Polyvalent Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 14. Global Pneumococcal Vaccine Polyvalent Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Type (2021-2032) Figure 16. 65 Years and Older Image Figure 17. 19 To 64 Years Old Image Figure 18. 18 Years and Younger Image Figure 19. Global Pneumococcal Vaccine Polyvalent Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 20. Global Pneumococcal Vaccine Polyvalent Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Application (2021-2032) Figure 22. Global Pneumococcal Vaccine Polyvalent Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 23. Global Pneumococcal Vaccine Polyvalent Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Application (2021-2032) Figure 25. North America Pneumococcal Vaccine Polyvalent Sales and Growth Rate (2021-2032) & (W Units) Figure 26. North America Pneumococcal Vaccine Polyvalent Sales Market Share by Country (2021-2032) Figure 27. U.S. Pneumococcal Vaccine Polyvalent Sales and Growth Rate (2021-2032) & (W Units) Figure 28. Canada Pneumococcal Vaccine Polyvalent Sales and Growth Rate (2021-2032) & (W Units) Figure 29. Mexico Pneumococcal Vaccine Polyvalent Sales and Growth Rate (2021-2032) & (W Units) Figure 30. Europe Pneumococcal Vaccine Polyvalent Sales and Growth Rate (2021-2032) & (W Units) Figure 31. Europe Pneumococcal Vaccine Polyvalent Sales Market Share by Country (2021-2032) Figure 32. Germany Pneumococcal Vaccine Polyvalent Sales and Growth Rate (2021-2032) & (W Units) Figure 33. France Pneumococcal Vaccine Polyvalent Sales and Growth Rate (2021-2032) & (W Units) Figure 34. U.K. Pneumococcal Vaccine Polyvalent Sales and Growth Rate (2021-2032) & (W Units) Figure 35. Italy Pneumococcal Vaccine Polyvalent Sales and Growth Rate (2021-2032) & (W Units) Figure 36. Netherlands Pneumococcal Vaccine Polyvalent Sales and Growth Rate (2021-2032) & (W Units) Figure 37. Asia Pacific Pneumococcal Vaccine Polyvalent Sales and Growth Rate (2021-2032) & (W Units) Figure 38. Asia Pacific Pneumococcal Vaccine Polyvalent Sales Market Share by Country (2021-2032) Figure 39. China Pneumococcal Vaccine Polyvalent Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Japan Pneumococcal Vaccine Polyvalent Sales and Growth Rate (2021-2032) & (W Units) Figure 41. South Korea Pneumococcal Vaccine Polyvalent Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Southeast Asia Pneumococcal Vaccine Polyvalent Sales and Growth Rate (2021-2032) & (W Units) Figure 43. India Pneumococcal Vaccine Polyvalent Sales and Growth Rate (2021-2032) & (W Units) Figure 44. Australia Pneumococcal Vaccine Polyvalent Sales and Growth Rate (2021-2032) & (W Units) Figure 45. South America, Middle East and Africa Pneumococcal Vaccine Polyvalent Sales and Growth Rate (2021-2032) & (W Units) Figure 46. South America, Middle East and Africa Pneumococcal Vaccine Polyvalent Sales Market Share by Country (2021-2032) Figure 47. Brazil Pneumococcal Vaccine Polyvalent Sales and Growth Rate (2021-2032) & (W Units) Figure 48. South Africa Pneumococcal Vaccine Polyvalent Sales and Growth Rate (2021-2032) & (W Units) Figure 49. Saudi Arabia Pneumococcal Vaccine Polyvalent Sales and Growth Rate (2021-2032) & (W Units) Figure 50. Turkey Pneumococcal Vaccine Polyvalent Sales and Growth Rate (2021-2032) & (W Units) Figure 51. Argentina Pneumococcal Vaccine Polyvalent Sales and Growth Rate (2021-2032) & (W Units) Figure 52. UAE Pneumococcal Vaccine Polyvalent Sales and Growth Rate (2021-2032) & (W Units) Figure 53. Egypt Pneumococcal Vaccine Polyvalent Sales and Growth Rate (2021-2032) & (W Units) Figure 54. Chile Pneumococcal Vaccine Polyvalent Sales and Growth Rate (2021-2032) & (W Units) Figure 55. Global Pneumococcal Vaccine Polyvalent Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Figure 58. North America Pneumococcal Vaccine Polyvalent Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Figure 60. Europe Pneumococcal Vaccine Polyvalent Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Pneumococcal Vaccine Polyvalent Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Pneumococcal Vaccine Polyvalent Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Pneumococcal Vaccine Polyvalent Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Pneumococcal Vaccine Polyvalent Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Pneumococcal Vaccine Polyvalent Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Prevnar 13
  • Pneumovax23
Applications
  • 65 Years and Older
  • 19 To 64 Years Old
  • 18 Years and Younger
Companies covered
  • Merck & Co.
  • Pfizer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pneumococcal Vaccine Polyvalent Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pneumococcal Vaccine Polyvalent Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Pneumococcal Vaccine Polyvalent Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Pneumococcal Vaccine Polyvalent Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Pneumococcal Vaccine Polyvalent Market Dynamics
  1. 2.1 Pneumococcal Vaccine Polyvalent Industry Trends
  2. 2.2 Pneumococcal Vaccine Polyvalent Industry Drivers
  3. 2.3 Pneumococcal Vaccine Polyvalent Industry Opportunities and Challenges
  4. 2.4 Pneumococcal Vaccine Polyvalent Industry Restraints
3 Pneumococcal Vaccine Polyvalent Market by Manufacturers
  1. 3.1 Global Pneumococcal Vaccine Polyvalent Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Pneumococcal Vaccine Polyvalent Sales by Manufacturers (2021-2026)
  3. 3.3 Global Pneumococcal Vaccine Polyvalent Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Pneumococcal Vaccine Polyvalent Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Pneumococcal Vaccine Polyvalent Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Pneumococcal Vaccine Polyvalent Manufacturers, Product Type & Application
  7. 3.7 Global Pneumococcal Vaccine Polyvalent Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Pneumococcal Vaccine Polyvalent Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Pneumococcal Vaccine Polyvalent Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Pneumococcal Vaccine Polyvalent Tier 1, Tier 2, and Tier 3
4 Pneumococcal Vaccine Polyvalent Market by Type
  1. 4.1 Pneumococcal Vaccine Polyvalent Type Introduction
  2. 4.1.1 Prevnar 13
  3. 4.1.2 Pneumovax23
  4. 4.2 Global Pneumococcal Vaccine Polyvalent Sales by Type
  5. 4.2.1 Global Pneumococcal Vaccine Polyvalent Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Pneumococcal Vaccine Polyvalent Sales by Type (2021-2032)
  7. 4.2.3 Global Pneumococcal Vaccine Polyvalent Sales Market Share by Type (2021-2032)
  8. 4.3 Global Pneumococcal Vaccine Polyvalent Revenue by Type
  9. 4.3.1 Global Pneumococcal Vaccine Polyvalent Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Pneumococcal Vaccine Polyvalent Revenue by Type (2021-2032)
  11. 4.3.3 Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Type (2021-2032)
5 Pneumococcal Vaccine Polyvalent Market by Application
  1. 5.1 Pneumococcal Vaccine Polyvalent Application Introduction
  2. 5.1.1 65 Years and Older
  3. 5.1.2 19 To 64 Years Old
  4. 5.1.3 18 Years and Younger
  5. 5.2 Global Pneumococcal Vaccine Polyvalent Sales by Application
  6. 5.2.1 Global Pneumococcal Vaccine Polyvalent Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pneumococcal Vaccine Polyvalent Sales by Application (2021-2032)
  8. 5.2.3 Global Pneumococcal Vaccine Polyvalent Sales Market Share by Application (2021-2032)
  9. 5.3 Global Pneumococcal Vaccine Polyvalent Revenue by Application
  10. 5.3.1 Global Pneumococcal Vaccine Polyvalent Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Pneumococcal Vaccine Polyvalent Revenue by Application (2021-2032)
  12. 5.3.3 Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Application (2021-2032)
6 Global Pneumococcal Vaccine Polyvalent Sales by Region
  1. 6.1 Global Pneumococcal Vaccine Polyvalent Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pneumococcal Vaccine Polyvalent Sales by Region (2021-2032)
  3. 6.2.1 Global Pneumococcal Vaccine Polyvalent Sales by Region (2021-2026)
  4. 6.2.2 Global Pneumococcal Vaccine Polyvalent Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pneumococcal Vaccine Polyvalent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Pneumococcal Vaccine Polyvalent Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Pneumococcal Vaccine Polyvalent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Pneumococcal Vaccine Polyvalent Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Pneumococcal Vaccine Polyvalent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Pneumococcal Vaccine Polyvalent Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Pneumococcal Vaccine Polyvalent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Pneumococcal Vaccine Polyvalent Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Pneumococcal Vaccine Polyvalent Revenue by Region
  1. 7.1 Global Pneumococcal Vaccine Polyvalent Revenue by Region
  2. 7.1.1 Global Pneumococcal Vaccine Polyvalent Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Pneumococcal Vaccine Polyvalent Revenue by Region (2021-2026)
  4. 7.1.3 Global Pneumococcal Vaccine Polyvalent Revenue by Region (2027-2032)
  5. 7.1.4 Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Pneumococcal Vaccine Polyvalent Revenue (2021-2032)
  8. 7.2.2 North America Pneumococcal Vaccine Polyvalent Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Pneumococcal Vaccine Polyvalent Revenue (2021-2032)
  11. 7.3.2 Europe Pneumococcal Vaccine Polyvalent Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Pneumococcal Vaccine Polyvalent Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Pneumococcal Vaccine Polyvalent Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Pneumococcal Vaccine Polyvalent Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Pneumococcal Vaccine Polyvalent Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck & Co.
  2. 8.1.1 Merck & Co. Company Information
  3. 8.1.2 Merck & Co. Business Overview
  4. 8.1.3 Merck & Co. Pneumococcal Vaccine Polyvalent Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck & Co. Pneumococcal Vaccine Polyvalent Product Portfolio
  6. 8.1.5 Merck & Co. Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer Pneumococcal Vaccine Polyvalent Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Pneumococcal Vaccine Polyvalent Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pneumococcal Vaccine Polyvalent Value Chain Analysis
  2. 9.1.1 Pneumococcal Vaccine Polyvalent Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pneumococcal Vaccine Polyvalent Production Mode & Process
  6. 9.2 Pneumococcal Vaccine Polyvalent Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pneumococcal Vaccine Polyvalent Distributors
  9. 9.2.3 Pneumococcal Vaccine Polyvalent Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst